Novartis: Two Pipeline Hits, But Balance Sheet and Cash Flow Make a Buyable Dip
Novartis dropped sharply after pelacarsen failed its Phase III goal. The headline is painful, but the company’s $284B market cap, $9.7B free cash flow, low leverage and a diversified portfolio - including radioligand therapy exposure - provide a foundation to absorb two near-term setbacks. This trade idea outlines a disciplined long entry, stop, an…